FRA
ALNY icon

Frank Rimerman Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Frank Rimerman Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$416K Buy
1,256
+6
+0.5% +$2.04K 0.03% 418
2025
Q4 		$497K Sell
1,250
-1
-0.1% -$443 0.03% 387
2025
Q3 		$570K Buy
1,251
+24
+2% +$9.77K 0.04% 341
2025
Q2 		$400K Buy
+1,227
New +$340K 0.03% 392

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Frank Rimerman Advisors's ALNY Position: Q1 2026 in Review

Frank Rimerman Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 0.48% in Q1 2026, buying an estimated $2.04K and bringing the position to 1,256 shares worth $416K. The position accounts for 0.03% of the portfolio, ranked #418.

Frank Rimerman Advisors first reported a position in ALNY in Q2 2025 and has held it in 4 quarters since. The position peaked at $570K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Frank Rimerman Advisors held 1,256 shares of Alnylam Pharmaceuticals worth $416K as of Q1 2026.
  • Frank Rimerman Advisors bought 6 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.04K.
  • Alnylam Pharmaceuticals made up 0.03% of Frank Rimerman Advisors's portfolio in Q1 2026, its #418 holding.
  • Frank Rimerman Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Frank Rimerman Advisors's Alnylam Pharmaceuticals position peaked at $570K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Frank Rimerman Advisors's 13F filing for Q1 2026, filed 29 Apr 2026.